Period:
Draw Mode:
| Volume | 3,149 |
|
|||||
| News | (3) | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Merck and Co Inc | MRK | NYSE | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.38 | 0.34% | 113.49 | 07:21:03 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 113.11 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 98 | 3,149 | - | 83.05 - 119.65 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 07:23:32 | 10 | US$ 113.37 | USD |
Merck and Co Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 3.35B | 29.52M | 2.53B | US$ 14.49B | US$ 28.97M | 1.11 | 0.30 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | US$ - | 2.60% | 06/14/23 | -74.46k | - |
Merck News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRK Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 110.04 | 114.48 | 108.47 | 110.94 | 8,142,076 | 3.45 | 3.14% |
| 1 Month | 117.82 | 118.625 | 108.47 | 113.48 | 6,624,126 | -4.33 | -3.68% |
| 3 Months | 106.14 | 119.65 | 102.44 | 111.37 | 7,175,259 | 7.35 | 6.92% |
| 6 Months | 110.36 | 119.65 | 96.36 | 109.97 | 8,030,176 | 3.13 | 2.84% |
| 1 Year | 90.17 | 119.65 | 83.05 | 100.55 | 8,726,384 | 23.32 | 25.86% |
| 3 Years | 81.17 | 119.65 | 70.89 | 85.21 | 10,499,906 | 32.32 | 39.82% |
| 5 Years | 61.51 | 119.65 | 59.80 | 82.41 | 10,399,773 | 51.98 | 84.51% |
Merck Description
| Pandion Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address the unmet needs of patients suffering from autoimmune diseases. The firm has combined a network-based conceptualization of the immune system in advanced protein engineering to develop TALON (Therapeutic Autoimmune reguLatOry proteiN) drug design and discovery platform. Its pipeline products are PT101, for the treatment of patients with moderate-to-severe ulcerative colitis and the treatment of patients with systemic lupus erythematosus; PT627; PT001; and others. |